Hims & Hers Health, Inc. (HIMS)
NYSE: HIMS · Real-Time Price · USD
26.15
+0.77 (3.03%)
At close: May 29, 2026, 4:00 PM EDT
26.09
-0.06 (-0.24%)
After-hours: May 29, 2026, 7:59 PM EDT
Hims & Hers Health Revenue
Hims & Hers Health had revenue of $608.10M in the quarter ending March 31, 2026, with 3.77% growth. This brings the company's revenue in the last twelve months to $2.37B, up 32.81% year-over-year. In the year 2025, Hims & Hers Health had annual revenue of $2.35B with 59.00% growth.
Revenue (ttm)
$2.37B
Revenue Growth
+32.81%
P/S Ratio
2.55
Revenue / Employee
$970,406
Employees
2,442
Market Cap
6.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.35B | 871.13M | 59.00% |
| Dec 31, 2024 | 1.48B | 604.51M | 69.32% |
| Dec 31, 2023 | 872.00M | 345.08M | 65.49% |
| Dec 31, 2022 | 526.92M | 255.04M | 93.81% |
| Dec 31, 2021 | 271.88M | 123.12M | 82.77% |
| Dec 31, 2020 | 148.76M | 66.20M | 80.18% |
| Dec 31, 2019 | 82.56M | 55.88M | 209.45% |
| Dec 31, 2018 | 26.68M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Elanco Animal Health | 4.89B |
| Dr. Reddy's Laboratories | 3.58B |
| Neurocrine Biosciences | 3.10B |
| Amneal Pharmaceuticals | 3.05B |
| Alkermes | 1.56B |
| Lantheus Holdings | 1.55B |
| BioCryst Pharmaceuticals | 885.72M |
| Supernus Pharmaceuticals | 776.83M |
HIMS News
- 3 days ago - Hims & Hers Expands Benefits for Active Subscribers With Eight New Health and Wellness Partners - Business Wire
- 3 days ago - Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders? - MarketBeat
- 3 days ago - Hims & Hers Health Slides: Investor presentation - Filings
- 9 days ago - HIMS Stock Crashed after Earnings. I Don’t Think the Growth Story Is Broken - TipRanks
- 10 days ago - Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry - Reuters
- 10 days ago - Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide - Business Wire
- 10 days ago - Hims & Hers Brings First-Time Access to Generic Semaglutide to Canada - Business Wire
- 12 days ago - Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment - Business Wire